연구동향 분석
박사

희귀의약품 정책의 영향 분석 및 국내 희귀질환 관련 의료이용 형평성 = The effects of orphan drug policy and equity in healthcare utilization for rare diseases in Korea

강대 2020년

논문상세정보
인용/피인용
' 희귀의약품 정책의 영향 분석 및 국내 희귀질환 관련 의료이용 형평성 = The effects of orphan drug policy and equity in healthcare utilization for rare diseases in Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료이용
  • 정책연구
  • 형평성
  • 희귀의약품
  • 희귀질환
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
356 0

0.0%

' 희귀의약품 정책의 영향 분석 및 국내 희귀질환 관련 의료이용 형평성 = The effects of orphan drug policy and equity in healthcare utilization for rare diseases in Korea' 의 참고문헌

  • 희귀질환자의 급여비 지출에 대한 합리적 관리방안
    김성옥 국민건강 보험공단 [2014]
  • 희귀질환 정부지원사업 현황 및 관리방안
    박현영 건강보험심사평가원 정 책동향. ;10(4):7-15 [2016]
  • 희귀의약품 제도의 국 가별 비교 연구
    박실비아 박은자 주민희 채수미 보건사회연구. ;33(2):525-548 [2013]
  • 희귀난치성질환자 의료비지원사업의 중 장기방향설정에 관한 연구
    박기수 보건복지부 경상대학교 [2006]
  • 희귀난치성 질환자의 의약품 접근성 제고방안
    고숙자 박은자 한국보건사회연구원 [2010]
  • 한국의료패널 자료를 이용한 의료이용의 수평적 형평성 분석
    최수민 제 3회 한국의료패널 학술대회 :481-495 [2011]
  • 한국의 보건의료의 부담과 수혜의 공평성
    문성현 사회보장연구. ;20 (1):59-81 [2004]
  • 한국보건사회연구원. 한국의 건강불평등 지표와 정책과제 260-261
    세종: 한국보건사회연구원. :260-261 [2013]
  • 질병에 따른 소득분위별 의료이용 불평등도 추이
    감신 김윤주 이원기 J Health Info Stat. ;43(3):223-230 [2018]
  • 제4차 국민건강증진종합계획. 보건복지부
    한국건강증진개발원 [2015]
  • 정책평가론(4th ed
    노화준 ) 파주: 현문사 [2008]
  • 의료패널 자료를 활용한 외래의료이용 및 의료비 지출의 형평성 분석
    김동진 보건복지포럼. ;1:76-89 [2012]
  • 의료기관 종별 소득계층간 의료이용 불평등
    이중협 임국환 보건경제와 정책연구. ;16(2):39-56 [2010]
  • 의료기관 종류를 고려한 의료이용 형평성 분석
    김진구 사회과학연구. 20 12;28(3):205-226
  • 신의료기술 등이 경제성 평가 및 활용을 위한 정책방안: 의약 품을 중심으로. 한국보건사회연구원
    이의경 기본연구과제 2005-02:45 [2005]
  • 소득수준별 보건의료서비스 이용 형평성 변화 분석
    김도영 사회과학연구, ;23(3):105-125 [2012]
  • 소득계층별 건강상태에 따른 의료이용 형평성 분석
    이용재 한국사회정책. ;17:1.267-290 [2010]
  • 보건복지부. 차상위 본인부담경감대상자 지원사업 안내. Available: h ttp://www.bokjiro.go.kr/welInfo/retrieveGvmtWelInfo.do?searchIntClId=01& welInfSno=360
    구현민 [Accessed 2019-11-22] [2019]
  • 보건경제학
    양봉민 파주: 나남출판사 [2013]
  • 국민의 건강수준 제고를 위한 건강 형평성 모니터링 및 사업 개발
    김동진 한국보건사회연구원 [2016]
  • 국민건강보험공단 빅데이터운영실
    표본코호트DB 사용제 매뉴얼 ver4.0. 2 015
  • 국내 희귀질환 현황 분석 및 지원 개선방안 도출
    고광필 보건복지부 [2019]
  • 건강불평등에 대한 개념분석
    권정옥 배선형 이은남 J Korean Acad Nur s Adm. ;21(1):20-31 [2015]
  • “보건의료이용의 형평성”
    권순만 양봉민 오주환 이수형 이태진 보건경제 연구. ;9(2);13-24 [2003]
  • van Doorslaer E. Socioeconomic inequalities in health : measurement , computation and statistical inference
    [1997]
  • and Shkukler C. The Charlson Comorbidity Index Can Be Used Prospectively to Identify Patients Who Will Incur High Future Costs
    9 ( 12 ) [2014]
  • and Purvina S. Impact of orphan durgs on Latvian budget .
    11 ( 59 ) . [2016]
  • and Kruntoradova K. Expe nditures and Availability of Orphan Drugs in the Czech Republic : Seven Year Experience
    15 ( 7 ) : A434 .
  • and Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012
    [2014]
  • Who Will Adopt the Orphan Drugs
    3:221-224 [1979]
  • Whitehead M. Inequalities in health : The Black report
    [1988]
  • What is wrong with orphan drug policies ?
    15 ( 8 ) :1185-91 . [2012]
  • WHO. (2008). "mhGAP: Mental Health Gap Action Programme: scaling up care for mental, neurological and substance use disorders".
  • W. The Expenditure and Reimbursement of Orphan Drug in Taiwan : Challenges and Opportunities
    19 ( 3 ) : A255 . [2016]
  • Van Doorslaer E. On the measurement of inequaliti es in health
    33:545 ? 57 [1991]
  • Van Doorslaer E. Measuring and testing for inequity in the delivery of health care
    35 ( 4 ) :716-733 . [2000]
  • Tsuchiya A. Orphan drugs and the NHS : should w e value rarity ?
    331:1016-1019 [2005]
  • Top 20 Orphan Drugs Availab ility , Pricing and Reimbursement in Slovakia : 2005-2012 Review
    17 ( 7 ) : A540 ? 41 . [2014]
  • The familial technique for linking maternal death with poverty
    363:23-27 [2004]
  • The Orphan Drug Act Restoring the Mission to Rare Diseases .
    201 6 ; 39:210-21000003 .
  • The Lagrange multiplier test and its applications to model specification in econometrics
    47 ( 1 ) :239-53 . [1980]
  • The European challenges of funding orphan medicinal products
    [2018]
  • The Budget Impact of Orphan Dr ugs in the US : A 2007-2013 MIDAS Sales Data Analysis
    [2019]
  • Tesar T. Eight years e xperience with availability and uptake of orphan drugs with or without pr ior EU orphan designation in Slovakia
    17 : A235 . [2014]
  • Tang W. Rare diseases , orphan dru gs , and their regulation in Asia : Current status and future perspectives . I ntractable & rare diseases research
    1 ( 1 ) :3 ? 9 . [2012]
  • System of Health Accounts ( SHA 201 1 )
    [2019]
  • Stefanov R. Budget Impact o f Rare Diseases : Proposal for a Theoretical Framework Based on Evidenc e from Bulgaria
    ( 242 ) :46 ? 53 . [2015]
  • State initiatives to control medicat ion costs ; can transparency legislation help ?
    374:230 1 ? 04 [2016]
  • Soria-Soto M. Analysis and Evolution of Spending on O rphan Drugs
    24 : A57 . [2017]
  • Social-class inequality in infant mortality in England and Wal es from 1921-1980
    4 ( 1 ) :1-21 . [1988]
  • Simoens S. Drugs for rare diseases-or phan designation status influences price .
    9:1-5 [2011]
  • Sherman B. Sunset Implementation : A Positive Partnership to m ake Government Work
    28 ( 1 ) :78-81 [1978]
  • S.Calculating Income Distribution Indices from Microdata .
    41 ( 1 ) :139 ? 42 . [1988]
  • Rovira J. Assessing the eConomicChallenges posed by orphan drugs
    23:36-42 [2007]
  • Relating price determi nation to disease prevalence
    341 : c4615 . [2010]
  • RareCancers : a sea of oppor tunity .
    17 : e52-e61 [2016]
  • Rare Diseases and Orphan Products : Accelerati ng Research and Development
    Available : https : //www.ncbi.nlm.nih.gov/books /NBK56184/ [2010]
  • Quasi-experimentation : Design Analysis Is sues for Field Settings
    [1979]
  • Public Expenditure on Auth orised Orphan Drugs in theCzech Republic Between 2008 and 2013
    17 : A526 [2014]
  • Prices and availability of biopharmaceuticals : an internationalComparison
  • Policies for Orph an Diseases and Orphan Drugs
    [2009]
  • Pharmaceutical spending
    [2019]
  • Petrova G. National health insurance fund cost analysis for rare cancer diseases and orphan drugs .
    17 ( 1 ) :13 ? 18 . [2015]
  • Pani L. The ‘ Weight ’ of Orphan Drugs in the European Pharmaceutical Policy . A Focus on the Ex penditure and the Utilization of Orphan Drugs in Five European Union C ountries
    15 ( 4 ) : A20 . [2012]
  • Panel Data and Unobservable Individual Effects
    [1981]
  • Paci P. Equity in the Finance and Deliver y of Health Care : Some Tentative Cross-Country Comparisons
    1989:5 ( 1 ) ; 89-112
  • Outrageous prices of orphan drugs : a call for collaboration
    392:791-94 [2018]
  • Orphan Drug Act of 1983 Availabl e
    https : //www.fda.gov/media/99546/download [2018]
  • O. Hori zontal Equity in Health Care Utilization Evidence from Three High-incom e Asian Countries
    2007:64 ( 1 ) ; 199-212
  • New approach to cancer therapy ba sed on a molecularly defined cancer classification
    6 4:70 ? 74 [2014]
  • Methods of Measuring the Concentration of Wealth
    9 ( 70 ) :209-219 . [1905]
  • Matusewicz W. The availability a nd Expenditure of Orphan Medicines in Poland .
    1 8 : A304 [2015]
  • M. Predicted versus Actual Budget Impact of High-Cost Drugs in Ireland
    17 ( 7 ) : A426 ? 27 [2014]
  • Longitudinal Changes in Prevalence of Rare Diseas es and Related Costs in Taiwan ( 2003-2014 )
    25:122-23 [2016]
  • L. Determinants and Equity Evaluation for H ealth Expenditure Among Patietns with Rare diseases in China .
    129 ( 112 ) :1387~1393 [2016]
  • Kosztolanyi G. Shift of focus in the fina ncing of Hungarian drugs . Reimbursement for orphan drugs for treating rare diseases : financing of enzyme replacement therapy in Hungary
    155 ( 44 ) :1735 ? 41 . [2014]
  • Kos M. Patient Access to Medicines for Rare Disea ses in European Countries .
    21 ( 5 ) :553 ? 60 . [2018]
  • Koolman X. Inequalities in access to medi cal care by income in developed countries
    174 ( 2 ) :177-183 . [2006]
  • Kaura S. Pharmace utical expenditure on drugs for rare diseases in Canada : a historical ( 200 7 ? 13 ) and prospective ( 2014 ? 18 ) MIDAS sales data analysis .
    11 ( 68 ) . [2016]
  • Kaura S. Orphan Drug Exp enditures in the United States : A Historical and Prospective analysis , 200 7-18
    35 ( 9 ) :1588-1594 . [2016]
  • J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer
    305 ( 22 ) :2320-2326 . [2011]
  • Inequalities in medical care utilization by south korean cancer patients according to i ncome : a retrospective cohort study
    41 ( 1 ) :51-66 . [2011]
  • Hydroxyurea for the treatment of sickle cell anemia358:1362 ?
    69 [2008]
  • Hutchings A. Estimating the Budget Impact of Orp han Medicines in Europe : 2010 - 2020
    [2011]
  • Heme ls M. Do payers value rarity ? An analysis of the relationship between dis ease rarity and orphan drug prices in Europe
    5 ( 1 ) :1299665 . [2017]
  • Health inequalities : Europe in profile . An independent , e xpert report commissioned by the UK Presidency of the EU
    [2005]
  • Health Inequalities Policy in Korea : Cuttent Status and Future C hqallenges
    274 : S33-40 . [2012]
  • Handbook of Parametric and Nonparametric Statistical Proce dures
    2 nd Edition [2000]
  • Global Spending on Orphan D rugs in France , Germany , the UK , Italy and Spain during 2007
    8 ( 5 ) :301-315 . [2010]
  • Experimental and quasi-experimental designs for research
    [1963]
  • Evaluation Policyb
    [1976]
  • Evaluation : A Systematic Approach ( 7t h ed. )
    [2004]
  • Estimating the budget impact of orphan drugs in Sweden and France 2013-2020
    13 ( 9 ) :22 [2014]
  • Equity in the Finance of Health Car e : Some Further International Comparisons
    18 ( 3 ) :263-90 . [1999]
  • Economic costs of health inequ alities in the European Union
    65 ( 5 ) : 412-9 . [2011]
  • Disease and economic burden for rare diseases in Taiwan : A longitudinal study using Taiwan 's National Health Insurance Research Database
    13 ( 9 ) : e0204206 . [2018]
  • Delayed Access for Patients With Rare Diseases in Asia Pacifi c : Finding a Solution That Works .
    [2018]
  • Colak E. Orphan Drug Market Analysis in Turkey
    19 : A581 . [2016]
  • Budgetary Impact of Medicinal Therapies for Rare Diseases in Bulgaria .
    60 ( 1 ) :79 ? 91 [2018]
  • Budget impact analysis of drug s for ultra-orphan non-oncological diseases in Europe
    15 ( 1 ) :171-179 . [2015]
  • Budget Impact of Orphan Drugs in Denmark Compared to Other European Countries
    20 10 ; 13 ( 7 ) : A414
  • Barbeau M. Expenditures on Orphan Drugs in Cana da , Europe ( EU5 < Belgium , Sweden and the Netherlands ) and Australia in 2009
    15 ( 7 ) : A434 . [2012]
  • Are rare diseases still orphans or ha ppily adopted ? The challenges of developing and using orphan medicina l products
    62:264-271 [2006]
  • Access to Orphan Drugs : A Comprehensive Review of Legislations , Regulations and Policies in 35 Countries
    10 ( 10 ) : e0140002 . [2015]
  • A synthesis of drug reimbursement decision-making proc esses in organisation for econonmic Cooperation and development count ries
    17 ( 1 ) :98-108 [2014]
  • 98. Therapeutic Goods Regulations 1990 (Statutory Rules 1990) No. 394 (Aus tralia)
  • 97. The Pharmaceutical Affair Law 145-10 August 1960 ? Revised in 1993 (J apan)
  • 96. Taiwan MOHW. National Health Expenditure 2017. Available: https://www. mohw.gov.tw/cp-4271-46084-2.html [Accessed 2019; 7: 21]
  • 93. Survey of the delay in diagnosis for 8 rare diseases in Europe (‘Eurordis Care2’) Available : https://www.eurordis.org/publication/survey-delay-diagn osis-8-rare-diseases-europe-%E2%80%98eurordiscare2%E2%80%99 [Access ed: 2019; 6: 12]
  • 92. Suppe P. A Probabilistic Theory of Causality: Amsterdam, North Holland, 1970.
  • 90. Suchman E. Evaluative Research. New York: Russel Sage Foundation, 196 7:122-123.
  • 88. Simoens S. Pricing and reimbursement of orphan drugs: the need for m ore transparency. Orphanet J Rare Dis. 2011;6(1):42.
  • 79. Rinaldi A. Adopting an orphan. EMBO Rep. 2005;6:507-510.
    [2005]
  • 78. Regulation (EC) No 141/2000 of the European Parliament and of the Co uncil of 16 December 1999 on orphan medicinal products. Official Journ al of the European Communities. 2000;L018(43):1?6.
  • 77. Pomeranz K. Orphan Drug Report 2017. EvaluatepPharma, 2017.
  • 73. Pacific Bridge Medical. Orphan drugs in Asia 2017. https://www.pacificbr idgemedical.com/research-report/orphan-drugs-asia-report-2017/ [Accesse d 2019; 6: 19]
  • 72. Orphan drug Act, Public Law 97-414, 4 January 1983 (US). Available: htt ps://www.fda.gov/media/99546/download [Accessed 2019; 4: 12]
  • 71. Orphan Drug Act Title 21, Food and Drugs. Part 316-Orphan Drugs, 199 3. Available: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSe arch.cfm?CFRPart=316&showFR=1 [Accessed 2019; 4 :11]
  • 56. Levitan SA and Wurzburg G. Evaluating Federal Social Programs. Kalama zoo, Michigan: W.E. Upjohn Institute for Employment Research, 1979.
  • 55. Koolman X and Doorslaer E. On the interpretation of a cnocentration in dex of inequality. Health Econ. 2004;13:649-656
  • 54. Kohler U and Frauke K. Data Analysis Using Stata, 2nd ed: College Stati on, Texas, Stata Press Publication, 2005.
  • 46. Health Canada, Office of Legislative and Regulatory Modernization. Initial draft discussion document for a Canadian orphan drug regulatory frame work. 2012. Avaliable: https://www.raredisorders.ca/content/uploads/Prop osal-for-Orphan-Drug-Framework_dec-12-2012.pdf [Accessed 2018; 12: 1]
  • 45. IQVIA . Orphan Drugs in the United States: Exclusivity, Pricnig and Treat ed Populations. IQVIA Institute for Human Data Science. 2018. Available: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/orphan-drugs-in -the-united-states-exclusivity-pricing-and-treated-populations.pdf?_=15719 00259418 [Accessed 2019; 10: 23]
  • 44. IMF. GDP per capita database. Available:https://www.imf.org/external/data mapper/NGDPDPC@WEO/OEMDC/ADVEC/WEOWORLD/EUQ/ [Accessed 2 019; 6: 29]
  • 38. Harper M. The world most expensive drugs. Available: https://www.forbe s.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.h tml#2fb30c285e10 [Accessed: 2018; 11: 27]
  • 37. Hadjivasiliou A. Orphan Drug Report 2017. EvaluatepPharma (2017) Avail able: http://info.evaluategroup.com/rs/607-YGS-364/images/EPOD17.pdf [A ccessed: 2019; 5: 3]
  • 34. GARD: FAQs about rare diseases. Available: https://rarediseases.info.nih.go v/diseases/pages/31/faqs-about-rare-diseases [Accessed 2018; 12: 2]
  • 31. Finkel. Special Report. N Engl J Med. 1982;307:963-964.
  • 29. EURORDIS: About rare diseases. Available: http://www.eurordis.org/aboutrare-diseases. [Accessed: 2018; 12: 1]
  • 28. European Union. COMMISSION REGULATION (EC) No 847/2000 of 27 Ap ril 2000. Available: https://publications.europa.eu/en/publication-detail/-/pu blication/7f34e7b0-9c3c-4dab-9ba1-e088192a54c8 [Accessed:2018; 12:6]
  • 27. European Medicines Agency. Orphan Medicine figures. Available: http://w ww.ema.europa.eu/docs/en_GB/document_library/Other/2015/04/WC500185 766.pdf [Accessed: 2018; 11: 27]
  • 2. Australian government. Therapeutic Goods Regulations 1990 section 16H 1990. Available: https://www.legislation.gov.au/Details/F2018C00897 [Access ed 2019; 6: 18]
  • 12. WHO, Prevention and management of osteoporosis, in WHO Technical Report Series, W.S. Group, Editor. 2003.
  • 12. Carlos N. ‘The Political Economy of Hope:Patients’ Organizations, Science and Biovalue. BioSocieties. 2006;1(3):289?305.
  • 11. Carlos N. Orphan Drugs, Patient Activism and Contemporary Healthcare. Quaderni. 2009;68:13?23.
  • 109. WHO. Cardiovascular diseases: what are cardiovascular diseases? Genev a, World Health Organization. Available: https://www.who.int/health-topic s/cardiovascular-diseases/ [Accessed 2019;10:1]
  • 107. Wagstaff A. Inequality Aversion, Health Inequalities and Health Achieve ment. Journal of Helath Economics. 2002;21(4):627-41.
  • 100. US Food and Drug Administration. 2016 Novel Drugs Summary. Availab le: https://www.fda.gov/media/102618/download [Accessed 2019; 1: 12]
  • 1. America's Health Insurance Plans. Orphan Drug Utilization and Pricing pat tern (2012?2014). Available: https://www.ahip.org/wpcontent/uploads/2016/ 10/OrphanDrug_DataBrief_10.21.16.pdf [Accessed 2018; 11: 27]
  • -2015년 의료이용 불평등 변화 추이와 영향요인
    김진구 사회보장연 구. 2019;35(2):63-92 [2009]